Belgium vs Tunisia: Tuberculosis patients who tested positive for HIV
Belgium
24 patients
in 2021
Tunisia
16 patients
in 2021
Belgium rank
109th
Tunisia rank
112th
Tuberculosis patients who tested positive for HIV over time
- Belgium
- Tunisia
How they compare
Belgium currently reports 24 patients against 16 patients in Tunisia, a difference of 8 patients.
That makes Belgium's figure about 1.5 times Tunisia's.
Across all 17 years both countries report, Belgium has been ahead every year.
Belgium ranks 109th and Tunisia ranks 112th of 201 countries.
Belgium has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Belgium | Tunisia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 51.83 patients | 2.67 patients | 49.17 patients | Belgium |
| 2010s | 40.89 patients | 15.11 patients | 25.78 patients | Belgium |
| 2020s | 27.5 patients | 18.5 patients | 9 patients | Belgium |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher tuberculosis patients who tested positive for hiv, Belgium or Tunisia?
- Belgium, at 24 patients against 16 patients in Tunisia as of 2021.
- What is the difference in tuberculosis patients who tested positive for hiv between Belgium and Tunisia?
- 8 patients, with Belgium ahead.
- How many years of comparable data are there for Belgium and Tunisia?
- 17 years are reported by both, from 2004 to 2021.
- How do Belgium and Tunisia rank globally for tuberculosis patients who tested positive for hiv?
- Belgium ranks 109th and Tunisia ranks 112th of 201 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026); Population based on various sources (2024) – with minor processing by Our World in Data, published as Tuberculosis patients who tested positive for HIV. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated number of tuberculosis (new and relapsed) patients that tested positive for HIV.